JP2025524457A - 哺乳動物におけるキメラ抗原受容体介在性の免疫応答を刺激するための方法において使用するためのｃｄ１２３に対する標的化モジュール - Google Patents

哺乳動物におけるキメラ抗原受容体介在性の免疫応答を刺激するための方法において使用するためのｃｄ１２３に対する標的化モジュール

Info

Publication number
JP2025524457A
JP2025524457A JP2024575443A JP2024575443A JP2025524457A JP 2025524457 A JP2025524457 A JP 2025524457A JP 2024575443 A JP2024575443 A JP 2024575443A JP 2024575443 A JP2024575443 A JP 2024575443A JP 2025524457 A JP2025524457 A JP 2025524457A
Authority
JP
Japan
Prior art keywords
targeting module
seq
tag
receptor
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024575443A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025524457A5 (https=
Inventor
シュペア・ヨハネス
エーニンガー・アルミン
Original Assignee
アヴェンセル・セラピューティクス・インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP22180805.8A external-priority patent/EP4296281A1/en
Application filed by アヴェンセル・セラピューティクス・インコーポレイティド filed Critical アヴェンセル・セラピューティクス・インコーポレイティド
Publication of JP2025524457A publication Critical patent/JP2025524457A/ja
Publication of JP2025524457A5 publication Critical patent/JP2025524457A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/15—Non-antibody based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A61K2239/24—Dimerizable CARs; CARs with adapter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
JP2024575443A 2022-06-23 2023-06-23 哺乳動物におけるキメラ抗原受容体介在性の免疫応答を刺激するための方法において使用するためのｃｄ１２３に対する標的化モジュール Pending JP2025524457A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22180805.8 2022-06-23
EP22180805.8A EP4296281A1 (en) 2022-06-23 2022-06-23 Targeting modules against cd123 and a tag for use in a method for stimulating a universal chimeric antigen receptor-mediated immune response in a mammal
EP23168260.0 2023-04-17
EP23168260 2023-04-17
PCT/US2023/068998 WO2023250489A1 (en) 2022-06-23 2023-06-23 Targeting modules against cd123 for use in a method for stimulating a chimeric antigen receptor-mediated immune response in a mammal

Publications (2)

Publication Number Publication Date
JP2025524457A true JP2025524457A (ja) 2025-07-30
JP2025524457A5 JP2025524457A5 (https=) 2026-04-06

Family

ID=87281111

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024575443A Pending JP2025524457A (ja) 2022-06-23 2023-06-23 哺乳動物におけるキメラ抗原受容体介在性の免疫応答を刺激するための方法において使用するためのｃｄ１２３に対する標的化モジュール

Country Status (7)

Country Link
US (1) US20250269025A1 (https=)
EP (1) EP4543922A1 (https=)
JP (1) JP2025524457A (https=)
CN (1) CN119790072A (https=)
AU (1) AU2023289687A1 (https=)
CA (1) CA3258275A1 (https=)
WO (1) WO2023250489A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
EP3581200A1 (en) 2018-06-13 2019-12-18 GEMoaB Monoclonals GmbH Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders

Also Published As

Publication number Publication date
US20250269025A1 (en) 2025-08-28
CN119790072A (zh) 2025-04-08
WO2023250489A1 (en) 2023-12-28
EP4543922A1 (en) 2025-04-30
AU2023289687A1 (en) 2025-01-02
CA3258275A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
KR102898514B1 (ko) 다양한 다중 항원의 표적화를 위한 역방향 범용 키메라 항원 수용체 발현 면역 세포, 이의 제조 방법 및 암, 감염증 및 자가면역 장애의 치료를 위한 이의 용도
AU2017301880B2 (en) Immunomodulatory polypeptides and related compositions and methods
CN108884164B (zh) 用于免疫疗法的经修饰细胞
KR102813968B1 (ko) Ctla-4 변이체 면역조절 단백질 및 이의 용도
CN116829194A (zh) 用于工程化细胞疗法的靶向细胞因子构建体
US20220133792A1 (en) Signaling platforms for chimeric antigen receptor t cells
JP2022547416A (ja) Ｂ細胞標的化並列ＣＡＲ（ｐＣＡＲ）治療的薬剤
JP2025521025A (ja) スイッチ可能なキメラ抗原細胞表面受容体を含む操作されたヒトｔ細胞およびこれらを作製するための方法
US20230183351A1 (en) A targeting module comprising pd-l1 and/or pd-l2 for use in a method for stimulating a chimeric antigen receptor mediated immune response in a mammal
US20250302875A1 (en) TARGETING MODULES AGAINST IL13R-alpha-2 AND/OR HER2 FOR USE IN A METHOD FOR STIMULATING A CHIMERIC ANTIGEN RECEPTOR-MEDIATED IMMUNE RESPONSE IN A MAMMAL
US20250269025A1 (en) Targeting modules against cd123 for use in a method for stimulating a chimeric antigen receptor-mediated immune response in a mammal
EP4296281A1 (en) Targeting modules against cd123 and a tag for use in a method for stimulating a universal chimeric antigen receptor-mediated immune response in a mammal
EP4566619A1 (en) Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal
EP4566620A1 (en) Switchable universal chimeric antigen receptors and their use
EP4382119A1 (en) A kit for use in the treatment of hematological cancer
EP4342907A1 (en) Switchable chimeric antigen receptors and their use
AU2024393901A1 (en) Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed
JP2025540251A (ja) 血液癌の治療において使用するためのキット
HK40125821A (en) Switchable universal chimeric antigen receptors and their use
HK40125822A (en) Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal
JP2025524457A5 (https=)
CN117881695A (zh) 功能强化的新型嵌合抗原受体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260327